NASDAQ · RXRX
Healthcare · Biotechnology
$3.24
Up+$0.04 (+1.16%)
Updated Sep 16, 2026, 4:27 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RXRX closed at $3.24 after 20 trading sessions, up 4.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.37 | $3.37 | $3.22 | $3.24 | 11.88M |
| Sep 14, 2026 | $3.19 | $3.455 | $3.18 | $3.41 | 17.1M |
| Sep 11, 2026 | $3.21 | $3.25 | $3.15 | $3.20 | 8.03M |
| Sep 10, 2026 | $3.14 | $3.25 | $3.10 | $3.16 | 10.63M |
| Sep 9, 2026 | $3.42 | $3.45 | $3.21 | $3.215 | 14.2M |
| Sep 8, 2026 | $3.58 | $3.59 | $3.43 | $3.44 | 14.99M |
| Sep 4, 2026 | $3.415 | $3.70 | $3.41 | $3.63 | 29.04M |
| Sep 3, 2026 | $3.435 | $3.45 | $3.2901 | $3.44 | 13.75M |
| Sep 2, 2026 | $3.34 | $3.4891 | $3.285 | $3.38 | 14.05M |
| Sep 1, 2026 | $3.34 | $3.38 | $3.2801 | $3.33 | 10M |
| Aug 31, 2026 | $3.305 | $3.41 | $3.25 | $3.40 | 13.91M |
| Aug 28, 2026 | $3.40 | $3.45 | $3.31 | $3.34 | 10.56M |
| Aug 27, 2026 | $3.515 | $3.5499 | $3.42 | $3.44 | 10.99M |
| Aug 26, 2026 | $3.51 | $3.55 | $3.43 | $3.49 | 12.98M |
| Aug 25, 2026 | $3.27 | $3.59 | $3.26 | $3.56 | 22.52M |
| Aug 24, 2026 | $3.42 | $3.44 | $3.215 | $3.25 | 15.16M |
| Aug 21, 2026 | $3.39 | $3.6299 | $3.37 | $3.50 | 22.9M |
| Aug 20, 2026 | $3.40 | $3.46 | $3.27 | $3.34 | 21.45M |
| Aug 19, 2026 | $3.275 | $3.50 | $3.19 | $3.50 | 30.37M |
| Aug 18, 2026 | $3.03 | $3.10 | $2.92 | $3.09 | 16.35M |
The latest Smart Investors Daily articles mentioning RXRX.
RXRX research
Company profile and research snapshot.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| May 7, 2026 | Needham | Buy | — |
| Apr 30, 2026 | JP Morgan | Overweight | — |
| Feb 26, 2026 | Needham | Buy | — |
| Feb 26, 2026 | B of A Securities | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Recursion Pharmaceuticals, Inc. (RXRX) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsNajat Khan...
Yahoo · Sep 10, 2026
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
Yahoo · Sep 8, 2026
Don't catch a falling knife.
SeekingAlpha · Sep 5, 2026
Stay ahead with Wall Street Week Ahead: key earnings (Oracle, Adobe, Kroger), IPOs & CPI/PPI data, plus volatility/dividend watch. See more here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RXRX.
